6/4/2010

Abbott Laboratories said it received FDA clearance for the Architect HE4 blood test, which is designed to track ovarian cancer progression or recurrence. The product is already approved in Europe as well as in some countries in Asia and Latin America.

Full Story:
Canadian Business

Related Summaries